Form 4: Apellis GC Sells Shares Via Pre-Arranged 10b5-1 Plan

Apellis Pharmaceuticals General Counsel David O. Watson sold 5,000 shares of common stock for $20.06 per share as part of a pre-arranged 10b5-1 trading plan.

Summary

• David O. Watson, General Counsel of Apellis Pharmaceuticals, Inc. (APLS), reported a sale of common stock.
• The transaction involved the disposition of 5,000 shares of common stock.
• The shares were sold at a price of $20.06 per share.
• The sale occurred on November 17, 2025.
• This transaction was executed pursuant to a Rule 10b5-1 trading plan established on March 3, 2025.
• Following the transaction, Mr. Watson directly beneficially owns 108,730 shares of common stock.
• Additionally, Mr. Watson indirectly beneficially owns 10,000 shares through a custodial account for minor children and 50,136 shares through The David O. Watson Irrevocable Trust of 2023.

Sentiment

Score: 5

Explanation: The filing reports a routine, pre-scheduled insider stock sale under a 10b5-1 plan, which typically has a neutral impact on sentiment as it is not indicative of new company-specific positive or negative developments.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating it was not a reaction to recent negative company news.

Negatives

• No specific negatives are indicated by this routine insider transaction.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

N/A

Industry Context

This Form 4 filing is a routine disclosure of an insider stock transaction and does not provide information relevant to broader industry trends or competitive landscape.

Related Party Transactions

• David O. Watson disclaims beneficial ownership over shares held by The David O. Watson Irrevocable Trust of 2023 except to the extent of his pecuniary interest therein, with William Zorn as trustee.

Stakeholder Impact

• The sale of 5,000 shares by the General Counsel is a relatively small, pre-planned transaction and is unlikely to have a significant direct impact on shareholders, employees, customers, suppliers, or creditors.

Key Dates

Recommendation

This Form 4 reports a routine, pre-scheduled insider sale under a 10b5-1 plan. Such transactions are generally not considered indicative of a change in the company's fundamental prospects or a signal for investors to alter their positions. Therefore, a 'hold' recommendation is appropriate as this filing does not provide new information to warrant a change in investment thesis.

Keywords

Apellis Pharmaceuticals, APLS, Insider Trading, Form 4, Stock Sale, David O. Watson, General Counsel, 10b5-1 Plan